Metabolism of apo(a) and apoB100 of lipoprotein(a) in women: Effect of postmenopausal estrogen replacement

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 9, 1998, Pages 3267-3276

  Su, Wanfang ^a   Campos, Hannia ^a   Judge, Helena ^a   Walsh, Brian W ^c   Sacks, Frank M ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B100; ESTROGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HUMAN; LIPOPROTEIN SYNTHESIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN METABOLISM;

AGED; ANTIGENS, NEOPLASM; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; KINETICS; LIPOPROTEIN(A); MIDDLE AGED; PLACEBOS; POSTMENOPAUSE;

EID: 0031771532     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.9.3267     Document Type: Article

References (69)

1. White AL, Lanford RE. 1995 Biosynthesis and metabolism of lipoprotein(a). Curr Opin Lipidol. 6:75-80.
2. Marcovina SM, Morrisett JD. 1995 Structure and metabolism of lipoprotein(a). Curr Opin Lipid. 6:136-145.
3. Liu AC, Lawn RM. 1994 Vascular interactions of lipoprotein(a). Curr Opin Lipid. 5:269-273.
4. Rader DJ, Hoeg JM, Brewer HB. 1994 Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 120:1012-1025.
5. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. 1994 Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 271:999-1003.
6. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. 1992 Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 69:1251-1254.
7. Cremer P, Nagel D, Labrot B, et al. 1994 Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 24:444-453.
8. Ridker PM, Hennekens CH, Stampfer MJ. 1993 A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 270:2195-2199.
9. Jauhiainen M, Koskinen P, Ehnholm C, et al. 1991 Lipoprotein (a) and coronary heart disease risk: a nested case-control study of Helsinki Heart Study participants. Atherosclerosis. 89:59-67.
10. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. 1986 Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 74:758-765.
11. Labeur C, DeBacquer D, DeBacker G, et al. 1992 Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. Clin Chem. 38:2261-2266.
12. Solymoss BC, Marcil M, Wesolowska E, Gilfix BM, Lesperance J, Campeau L. 1993 Relation of coronary artery disease in women <60 years of age to the combined elevation of serum lipoprotein(a) and total cholesterol to high-density cholesterol ratio. Am J Cardiol. 72:1215-1219.
13. Farrer M, Game FL, Albers CJ, et al. 1994 Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. Arterioscler Thromb. 14:1272-1283.
14. Wang XL, Tam C, McCredie RM, Wilcken DE. 1994 Determinants of severity of coronary artery disease in Australian men and women. Circulation. 89:1974-1981.
15. Bolibar I, Thompson SG, von Eckardstein A, Sandkamp M, Assmann G. 1995 Dose-response relationships of serum lipid measurements with the extent of coronary stenosis: strong, independent, and comprehensive. Arterioscler Thromb Vasc Biol. 15:1035-1042.
16. Sunayama S, Daida H, Mokuno H, et al. 1996 Lack of increased coronary atherosclerosis risk due to elevated lipoprotein(a) in women ≥55 years of age. Circulation. 94:1263-1268.
17. Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K, et al. 1997 Lipoprorein(a) as a determinant of coronary heart disease in young women. Circulation. 95:329-334.
18. Bostom AG, Gagnon DR, Cupples LA, et al. 1994 A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation. 90:1688-1695.
19. Jenner JL, Ordovas JM, Lamon-Fava S., et al. 1993 Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. Circulation. 87:1135-1141.
20. Meilahn EN, Kuller LH, Matthews KA, Stein EA. 1991 Lp(a) concentrations among pre- and postmenopausal women over time: the healthy women study. Circulation. [Suppl II]84:2170 (Abstract).
21. Heinrich J, Sandkamp M, Kokott R, Schulte H, Assmann G. 1991 Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem. 37:1950-1954.
22. Kim CJ, Ryu WS, Kwak JW, Park CT, Ryoo UH. 1996 Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy. Arch Intern Med. 156:500-504.
23. Sacks FM, McPherson R, Walsh BW. 1994 Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med. 154:1106-1110.
24. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Fowler SE, Stillman RJ. 1994 Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotein A-I, and sex hormone-binding globulin due to two doses of conjugated equine estrogen with and without a progestin. Obstet Gynecol. 83:173-179.
25. Soma MR, Osnago-Gadda I, Paoletti R, et al. 1993 The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 153:1462-1468.
26. Shewmon DA, Stock JL, Rosen CJ, et al. 1994 Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb. 14:1586-1593.
27. Haines C, Chung T, Chang A, Masarei J, Tomlinson B, Wong E. 1996 Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. Arch Intern Med. 156:866-872.
28. Taskinen M-R, Puolakka J, Pyorala T, et al. 1996 Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thomb Vasc Biol. 16:1215-1221.
29. Darling GM, Johns JA, McCloud PI, Davis SR. 1997 Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med. 337:595-601.
30. Tuck CH, Holleran S, Berglund L. 1997 Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arterioscler Thromb Vasc Biol. 17:1822-1829.
31. Grodstein F, Stampfer MJ. 1995 The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 38:199-210.
32. Walsh BW, Schiff I, Rosner R, Greenberg L, Ravnikar V, Sacks FM. 1991 Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 325:1196-1204.
33. Angelin B, Olivecrona H, Reihner E, et al. 1992 Hepatic cholesterol metabolism in estrogen-treated men. Gastroenterology. 103:1657-1663.
34. Windler EE, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL. 1980 The estradiol-stimulated lipoprotein receptor of rat liver. J Biol Chem. 255:10464-10471.
35. Campos H, Walsh BW, Judge H, Sacks FM. 1997 Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab. 82:3955-3963.
36. Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE. 1990 Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest. 85:1542-1547.
37. Harkes L, Jurgens G, Holasek A, van Berkel TJ. 1988 In vivo studies on the binding sites for lipoprotein(a) on parenchymal and non-parenchymal rat liver cells. FEBS Lett. 227:27-31.
38. Krempler F, Kostner GM, Balzano K, Sandhofer F. 1980 Turnover of lipoprotein(a) in man. J Clin Invest. 65:1483-1490.
39. Krempler F, Kostner GM, Roscher A, Haslauer F, Bolzano K, Sandhofer F. 1983 Studies on the role of specific cell surface receptors in the removal of lipoprotein(a) in man. J Clin Invest. 71:1431-1441.
40. Knight BL, Perombelon YF, Soutar AK, Wade DP, Seed M. 1991 Catabolism of lipoprotein(a) in familial hypercholesterolemic subject. Atherosclerosis. 87:227-237.
41. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB. 1993 Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest. 91:443-447.
42. Rader DJ, Cain W, Ikewaki K, et al. 1994 The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rates. J Clin Invest. 93:278-2763.
43. White AL, Lanford RE. 1994 Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem. 29:28716-28723.
44. Edelstein C, Davidson NO, Scanu AM. 1994 Oleate stimulates the formation of triglyceride-rich particles containing apoB100-apo(a) in long-term primary cultures of human hepatocytes. Chem Phys Lipids 67/68:135-143.
45. Wilkinson J, Munro LH, Higgins JA. 1994 Apolipoprotein(a) is not associated with apolipoprotein B in human liver. J Lipid Res. 35:1896-1901.
46. Frank S, Krasznai K, Durovic S, et al. 1994 High level expression of various apolipoprotein(a) isoforms by 'transferrinfection': the role of kringle-IV sequences in the extracellular association with low density lipoproteins. Biochemistry. 33:12329-12339.
47. Bonen DK, Hausman AM, Hadjiagapiou C, Skarosi SF, Davidson NO. 1997 Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). J Biol Chem. 272:5659-5667.
48. Walsh BW, Li H, Sacks FM. 1994 Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res. 35:2083-2093.
49. McLean JW, Tomlinson JE, Kuang WJ, et al. 1987 cDNA sequence of human apolipoprotein(a) is homologus to plasminogen. Nature. 330:132-137.
50. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. 1995 Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 41:246-255.
51. Henriksson P, Angelin B, Berglund L. 1992 Hormonal regulation of serum Lp(a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest. 89:1166-1171.
52. Frazer KA, Narla G, Zhang JL, Rubin EM. 1995 The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat Genet. 9:424-431.
53. Rader DJ, Mann WA, Cain W, et al. 1995 The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest. 95:1403-1408.
54. Thiery J, Armstrong VW, Schleef J, Creutzfeldt C, Creutzfeldt W, Seidel D. 1988 Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr. 66:462-463.
55. Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L. 1988 Effects of lovastatin alone and in combination with cholestyramine on serum lipids, and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis. 73:135-141.
56. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. 1989 HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 80:1313-1319.
57. Hunninghake DB, Stein EA, Mellies MJ. 1993 Effects of one year of treatment with pravastatin, an HMG CoA reductase inhibitor, on lipoprotein (a). J Clin Pharmacol. 33:574-580.
58. Bartens W, Kramer-Guth A, Wanner C. 1997 Corticotropin increases the receptor-specific uptake of native low-density lipoprotein (LDL)-but not of oxidized LDL and native or oxidized lipoprotein(a)-in HepG2 cells: no evidence for Lp(a) catabolism via the LDL receptor. Metabolism. 46:726-729.
59. Snyder ML, Hay RV, Whitington PF, Scanu AM, Fless GM. 1994 Binding and degradation of lipoprotein(a) and LDL by primary cultures of human hepatocytes. Comparison with cultured human monocyte-macrophages and fibroblasts. Arterioscler Thromb. 14:770-779.
60. Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK. 1997 The atherogenic lipoprotein(a) Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest. 100:2170-2181.
61. Edelstein C, Italia JA, Scanu AM. 1997 Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments. J Biol Chem. 272:11079-11087.
62. Seed M, O'Connor B, Perombelon N, O'Donnell M, Reaveley D, Knight BL. 1993 The effect of nicotinic acid and acipimox on lipprotein(a) concentration and turnover. Atherosclerosis. 101:61-68.
63. Cayol M, Boirie Y, Prugnaud J, Gachon P, Beaufrere B, Obled C. 1996 Precursor pool for hepatic protein synthesis in humans: effects of tracer route infusion and dietary proteins. Am J Physiol. 270:E980-E987.
64. Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech L, Brewer HB. 1993 Evaluation of apoA-I kinetics in humans using simultaneous stable isotope and exogenous radiotracer methods. J Lipid Res. 34:2207-2215.
65. Morrisett JD, Gaubatz JW, Nava MN, et al. 1993 Metabolism of apo(a) and apoB-100 in human lipoprotein(a). In: Catapano AL, Gotto AM, Smith LC, Paoletti R, ed. Drugs affecting lipid metabolism. Dordrecht, The Netherlands: Kluwer Academic Publishers and Fondazione Giovanni Lorenzini; 161-167.
66. Lichtenstein AH, Cohn JS, Hachey DL, Millar JS, Ordovas JM, Schaefer EJ. 1990 Comparison of deuterated leucine, valine, and lysine in the measurement of human apolipoprotein A-1 and B-100 kinetics. J Lipid Res. 31:1693-1701.
67. Chiesa G, Hobbs HH, Koschinsky ML, Lawn RM, Maika SD, Hammer RE. 1992 Reconstitution of lipoprotein[a] by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein[a]. J Biol Chem. 267:24369-24374.
68. White AL, Hixson JE, Rainwater DL, Lanford RE. 1994 Molecular basis for "null" lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon. J Biol Chem. 269:9060-9066.
69. Sacks FM, Campos H, Judge H, Walsh BW. 1997 Estrogen treatment and human lipoprotein metabolism. In: Forte TM, ed. Hormonal, metabolic, and cellular influences on cardiovascular disease in women. Armonk, NY: Futura Publishing Co; 229-246.